May 19th, 2020 – Portal Instruments was invited by UBS to present Portal’s needle-free drug delivery platform at the USB Global Healthcare Conference. Patrick Anquetil, CEO Portal Instruments, gave a presentation highlighting Portal’s needle-free injector and recent milestones.
Portal Instruments is a venture-backed medical device company, developing and commercializing a connected, needle-free drug delivery platform to transform the administration of medications for chronic diseases. Portal aims to improve the patient experience and outcomes through an innovative needle-free injector with connectivity, analytics, and a companion digital experience. The company has completed a landmark deal with Takeda to bring this vision to the market with a drug/device combination product in the field of Inflammatory Bowel Diseases. Portal Instruments’ Quality Management System is ISO 13485 certified. For more information, please visit www.portalinstruments.com or follow @portalcambridge on Twitter.
Portal’s platform is in development and not available for sale or use.